Millennium Prostate Cancer Agent Selected For FDA Continuous Marketing Application Pilot
This article was originally published in The Pink Sheet Daily
Executive Summary
The monoclonal antibody-linked chemotherapeutic MLN2704 is in a Phase I/II study for metastatic androgen-independent prostate cancer.